Souhaitez-vous accéder aux communiqués récents ?

Since its founding in 2018, JETOUR has consistently upheld its "Travel+" strategy, dedicated to creating reliable vehicles for the "Travel+"

DALIAN, China, March 30, 2026 (GLOBE NEWSWIRE) -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”), a leading lithium-ion battery manufacturer and electric energy...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated...

LONDON, March 30, 2026 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, has announced structural and strategic changes to the EMEA regional operations...

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the...

Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep...

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra...

Dubai, UAE, March 28, 2026 (GLOBE NEWSWIRE) -- The Pepeto team confirmed a major update to the exchange infrastructure as the presale pushes past $8.47 million with entries arriving faster every...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...